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Abstract
T-cell recognition of minor histocompatibility antigens (MiHA) plays an important role in the graft-versus-tumor (GVT) effect of
allogeneic stem cell transplantation (allo-SCT). However, the number of MiHA identified to date remains limited, making
clinical application of MiHA reactive T-cell infusion difficult. This study represents the first attempt of genome-wide prediction
of MiHA, coupled to the isolation of T-cell populations that react with these antigens. In this unbiased high-throughput MiHA
screen, both the possibilities and pitfalls of this approach were investigated. First, 973 polymorphic peptides expressed by
hematopoietic stem cells were predicted and screened for HLA-A2 binding. Subsequently a set of 333 high affinity HLA-A2
ligands was identified and post transplantation samples from allo-SCT patients were screened for T-cell reactivity by a
combination of pMHC-tetramer-based enrichment and multi-color flow cytometry. Using this approach, 71 peptide-reactive T-
cell populations were generated. The isolation of a T-cell line specifically recognizing target cells expressing the MAP4K1IMA
antigen demonstratesthatidentificationofMiHAthrough thisapproachisinprinciple feasible.However,withthe exceptionof
the known MiHA HMHA1, none of the other T-cell populations that were generated demonstrated recognition of
endogenously MiHA expressing target cells, even though recognition of peptide-loaded targets was often apparent. Collec-
tively these results demonstrate the technical feasibility of high-throughput analysis of antigen-specific T-cell responses in
small patient samples. However, the high-sensitivity of this approach requires the use of potential epitope sets that are not
solely based on MHC binding, to prevent the frequent detection of T-cell responses that lack biological relevance.
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Introduction
Patients with hematological malignancies can be successfully
treated with HLA-matched allogeneic stem cell transplanta-
tion (allo-SCT) and subsequent donor lymphocyte infusion (DLI)
[1,2]. The graft-versus-leukemia (GVL) effect of this successful
immunotherapy is due to recognition by donor T-cells of minor
histocompatibility antigens (MiHA) expressed on malignant
hematopoietic recipient cells [3–6]. These MiHA result from
genetic polymorphisms between donor and recipient that alter the
HLA-associated peptide repertoire, and are therefore capable to
elicit a potent T-cell response in the context of self-HLA [7].
Unfortunately, most MiHA are not solely expressed on hemato-
poietic cells but display a broad expression pattern in nonmalig-
nant recipient tissues. As a consequence, DLI can induce or
enhance graft-versus-host disease (GVHD), one of the main causes
of transplant-related morbidity and mortality [8,9]. It is assumed
that the selective infusion of T-cells reactive with MiHA exclu-
sively expressed on recipient hematopoietic cells would help to
separate the beneficial GVL effect from GVHD, and identification
of MiHA with a hematopoietic expression pattern is therefore of
interest.
To date, the number of known MiHA that form attractive
targets for antigen-selective cell therapy remains limited. As a
consequence of the requirement for both the relevant MiHA
mismatch between donor and recipient and expression of the
relevant HLA restriction molecule, the percentage of patients that
can be treated with such MiHA-selective cell therapy remains
low [10]. Considering the complex gene expression profiles in
hematopoietic cells [11] and the enormous number of known
allelic polymorphisms [12], the existence of many more clinically
applicable MiHA seems reasonable.
Several biochemical and molecular methods have successfully
led to the identification of MiHA including peptide elution from
HLA, cDNA library screening, genetic linkage analysis, and
genome-wide association analysis [7,13–16]. These methods
identified MiHA using a forward immunology approach, based
on the characterization of epitopes recognized by T-cells isolated
during a GVL response.
The use of soluble fluorescently labeled multimeric peptide-
MHC (pMHC) complexes has become a widely used approach to
detect antigen-specific T-cells in a diverse T-cell repertoire [17].
Furthermore, the development of technology for high-throughput
pMHC production [18,19], makes it possible to also screen for T-
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cytometry either by combinatorial encoding [20], or by extension
of the number of fluorescent labels used for pMHC tetramer
labeling [21,22].
In this study we set out to determine whether genome-wide
identification of MiHA by pMHC-tetramer screening is feasible.
In addition, we assessed whether these screens are possible in an
unbiased approach, in which patient are screened with a fixed set
of pMHC tetramers. To this purpose, we first predicted a large
number of potential MiHA epitopes using HLA-peptide binding
algorithms, single nucleotide polymorphism (SNP) data and gene-
expression databases. Subsequently, flow cytometry-based high-
throughput analysis of antigen-specific T-cell responses, followed
by functional testing of identified T-cell clones was used to assess
the clinical value of predicted MiHA. This unbiased screen
resulted in the generation of a large number of pMHC tetramer
positive T-cell lines. Subsequent functional analysis demonstrated
the isolation of two high-affinity T-cell populations specific for the
known HMHA-1 MiHA as well as a previously unknown epitope.
However, since this novel epitope was not produced to a sufficient
level by the endogenous antigen presentation machinery, it should
not be considered a bona fide MiHA.
Two major conclusions can be drawn from our study: First, high-
throughput analysis of antigen-specific T-cell responses in small
patient samples is technically feasible using the highly sensitive
technologies developed here. Second, when such screens are
performed using unbiased peptide sets that are based on epitope
binding, irrespective of peptide processing data and SNP status
of donor and recipient, the vast majority of T-cell responses
detected are of insufficient avidity to allow recognition of
endogenously produced antigen, or are directed against epitopes
that are not naturally presented to a sufficient extent to allow T-cell
recognition.
Results
Identification of genes with a hematopoiesis-restricted
expression pattern
In many hematological malignancies it is likely to be essential to
therapeutically target not only the differentiated leukemic cells, but
also the leukemic stem cell fraction, because of this, genes that are
expressed in hematopoietic precursor cells are of interest as a
potential source of MiHA, as these genes are likely to be expressed
in leukemic precursor cells as well. To obtain a better insight into
the gene expression profiles of specific hematopoietic cell fractions,
we performed microarray analyses on hematopoietic stem cells
purified from bone marrow, G-CSF mobilized peripheral blood
and cord blood. Both CD34
+/CD38
2 and CD34
+/CD38
+ frac-
tions were analyzed, representing early and more committed
hematopoietic stem cells, respectively. Subsequently, these data
were merged with gene expression data for similar and other cell
types from the NCBI GEO database [23], to identify genes
expressed in stem cells with a hematological restricted pattern.
The robustness of the approach was shown by the identification of
known hematopoiesis-restricted MiHA encoding genes such as
HMHA-1 and PTPRC (CD45). In addition, ubiquitous and non-
hematopoiesis tissue specific genes like KLK2 and GAPD, were
also found to have the expected expression profiles, demonstrating
that this combined database was sufficiently robust to identify
genes with a hematopoiesis-restricted expression pattern (e.g.
ITGB2 and FLT3 (Figure S1a–f). The combined database was
subsequently used to identify 79 non-Y-chromosomal genes that
are relatively specifically expressed in hematopoiesis-restricted cell
subsets (Table S1).
SNP identification in selected genes
The molecular basis for the immunogenicity of most MiHA is
formed by amino acid changes in MHC-restricted epitopes that
occur as a consequence of single nucleotide polymorphisms. Iden-
tification of such SNPs within our 79 hematopoiesis-restricted
genes using the NCBI’s dbSNP polymorphism database [24]
revealed 315 SNPs, of which the majority was nonsynonymous. In
addition, as MiHA have been reported to also be encoded by
alternative reading frames [5,6] (ARF) we also included synony-
mous SNPs to ensure no MiHA encoded by ARF were left out. At
the time of this SNP selection (dbSNP build 126), allele frequencies
were unknown for many of these SNPs, and SNPs with an un-
known allele frequency were included.
Prediction of MiHA epitope candidates
To predict potential MiHA epitopes encoded by this set of
SNPs, we generated peptide sequences in silico, based on the
nucleotide sequences of both allelic variants of the SNP. Peptide
sequences were generated both from the canonical and from the
two alternative forward reading frames, using gene segment
encoding ten amino acids N-terminal and C-terminal of the SNP-
containing codon. This peptide sequence set was then used to
predict 9-, 10- and 11-mer polymorphic HLA-A2 binding peptides
using three different HLA-peptide binding algorithms, Syfpeithi
[25], Bimas [26] and netMHC [27]. Predicted HLA-A2 binding
peptides were selected for further testing when at least passing the
threshold for one of the three algorithms. Peptides predicted from
an ARF were only selected if an upstream alternative start site was
detected. In total, 973 unique peptides were selected with a
predicted HLA-A2 binding affinity (Table S2). The successful
prediction of known MiHA such as HMHA-1, indicated that the
quality of the gene-expression and SNP databases combined with
HLA-peptide binding algorithms was sufficient to predict putative
MiHA (Figure S1g,h).
Assessing the HLA-A2 binding affinity of predicted MiHA
epitopes
To evaluate the HLA-A2 affinity of these predicted MiHA, the
set of 973 peptides was synthesized and analyzed using two
different MHC binding assays (‘‘MHC ELISA’’ and ‘‘MHC bead
assay’’) that are both based on UV-induced conditional ligand
cleavage, followed by peptide affinity dependent rescue of the
MHC complex [18,28], [29] (Figure 1). To set selection thresholds
for both binding assays, a number of control peptides with high,
intermediate or low HLA-A2 affinity were included. Peptide-
MHC rescue scores (RS) were determined in both assays and
normalized to the high affinity CMV-pp65NLV peptide [30].
Results of both assays showed a clear correlation and all control
peptides demonstrated the expected HLA-A2 affinity. Based on
this analysis, 333 peptides with RS$57 (MHC-ELISA) or RS$60
(MHC-bead assay) were selected (Table S3).
Analysis of efficiency and sensitivity for pull down of
MiHA specific T-cell populations
Antigen specific T-cells can be present at very low frequencies.
MiHA specific T-cell responses may therefore go undetected,
especially when analyzed directly ex vivo in clinical specimens that
often contain only a few million cells and that are generally not
obtained during the peak GVL response. To allow high-
throughput screening with a very large unbiased set of pMHC
tetramers in PBMC samples with low cell numbers, we first
developed an approach to simultaneously isolate T-cells reactive
with any of the pMHC tetramers, and then expand these T-cells in
High-Throughput MiHA Identification
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this approach, we attempted the detection of a MiHA specific T-
cell population in an allo-SCT patient PBMC sample obtained at
15 months after DLI, and in which HMHA-1 specific T-cells were
barely detectable (,0.01% of CD8
+ T-cells) ex vivo. After
magnetic pull down with the entire PE-labeled 333 pMHC
tetramer set and subsequent expansion of the cells, HMHA-1
reactive T-cells were clearly detectable at a frequency of 2.56% of
total CD8
+ T-cells (Figure S2). Thus, magnetic pull down with
large collections of pMHC tetramers can be used to facilitate
detection of low-level T-cell responses.
Identification of MiHA specific T-cell populations
Having successfully established the feasibility of our pull down
and in vitro expansion method for the detection of MiHA specific
T-cells in small PBMC samples, we subsequently utilized the entire
set of 333 PE-labeled pMHC tetramers to pull down MiHA
specific T-cells from 20 HLA-A2 positive allo-SCT patients with
various hematologic malignancies. Selected patients all demon-
strated a clear graft versus leukemia response after DLI, and
samples were obtained at the memory phase of the GVL response,
when MiHA specific T-cells are expected to be present but at low
frequencies. Following magnetic isolation, isolated cells were
expanded in vitro until cell numbers allowed the detection of
MiHA-reactive T-cell populations by MHC tetramer combinato-
rial encoding [19,20,28,31]. For this purpose, a set of fluorescently
labeled pMHC tetramers was generated in which each specific
pMHC complex was encoded by a unique combination of
fluorochromes [20], to screen for recognition of all 333 selected
epitopes in a limited number of stainings. The total set of selected
epitopes was hierarchically clustered to 16 groups of up to 25
unique pMHC complexes according to the order of priority, i.e.
SNP frequencies and HLA-A2 affinity (Table S3).
After pull down and an average of two weeks of expansion, flow
cytometric analysis of these samples revealed 71 different pMHC
tetramer-reactive T-cell populations, specific for 47 unique pMHC
complexes (Table S4). In most cases, T-cell frequencies varied
between 0.02% and 4.9% of total CD8
+ T-cells. A representative
example of a full panel with 25 different 2-color coded pMHC
complexes is shown in Fig. 2a, in which 3 potential MiHA-
tetramer reactive T-cell populations were observed for the pre-
dicted MiHA peptides 89 (0.11%),104 (0.22%) and 109 (0.17%).
In one patient we detected a T-cell population specific for the
previously identified HMHA-1H epitope.
To assess thepeptidespecificity and functional activityof these T-
cell populations we selected the 21 most interesting MiHA specific
T-cell populations for the generation of cell lines by pMHC
tetramer based cell sorting (Figure 2b–e). We based our selection on
favorable SNP allele frequencies according to the dbSNP database
and focused on T-cell populations that only showed reactivity with
one ofthe allelic counterparts of a specificpeptide. Thepurity of cell
lines generated in this manner was verified by pMHC tetramer
staining and 2 representative examples are shown in Figure S2c–d.
We were able to generate cell lines with sufficient purity for
subsequent functional assessment for 17 out of 21 selected T-cell
populations.
Assessing the functionality of isolated T-cell lines by
peptide stimulation
To analyze the functional activity of the isolated pMHC
tetramer specific T-cells, we measured IFN c production upon
incubation with peptide-loaded HLA-A2
+ target cells. As our T-
cell isolations were solely based on pMHC tetramer reactivity and
not on functional activity, we also measured the overall IFN c
secretion capacity of these cells, by nonspecific stimulation with
aCD3/CD28 stimulation beads (Figure 3a). Although IFN c
production capacity varied, peptide specific IFN c production
could be demonstrated for 10 out of 17 pMHC tetramer positive
cell lines, including 9 cell lines directed against potential MiHA
and one directed against the known HMHA-1 epitope. Six
cultures only demonstrated IFN c production when stimulated
with stimulation beads, indicating that these cell lines were not
functionally reactive to peptide antigen. In addition, pMHC-
tetramer positive cell line P235 PRKCB1RIG totally lacked IFN c
production capacity.
Peptide-specificity of the 10 T-cell lines that produced IFN-c
upon peptide stimulation was confirmed by assessing TCR
internalization upon stimulation with peptide-loaded target cells
(Figure 3b). TCR downregulation clearly correlated with IFN c
production and was observed for all cell lines that demonstrated
peptide specific IFN c production. Minimal downregulation was
observed for the four tested cell lines that lacked peptide specific
IFN c production, as well as the cell line that showed no overall
IFN c producing capacity. Hence, these data indicate that 10 out
of 17 tested cell lines are reactive against their specific peptide
when added exogenously.
Wide range of peptide affinity observed for pMHC
tetramer positive T-cell populations
To examine the ligand sensitivity of the generated peptide
specific cell lines, INF-c production was measured after stimula-
tion with T2 cells that were loaded with a range of peptide con-
centrations (Figure 4). In this assay (performed for 8 representative
cell lines), peptide concentrations required for T-cell recognition
Figure 1. HLA-A2 affinity of predicted peptides measured in
parallel by two different assays. HLA-A2 affinity of 973 predicted
MiHA peptides was measured in parallel by two different binding
assays. Each dot (black) represents a pMHC complex rescued by a tested
peptide after UV induced cleavage of a conditional ligand. On the y-axis
rescue score (RS) are shown for MHC-ELISA assay. On the x-axis RS are
shown for MHC-bead assay. RS are normalized to the HLA-A2 high
affinity CMV-pp65NLV peptide and CMV-pp65NLV peptide RS set to 100
for both assays. Selection threshold: RS$57 (MHC-ELISA) and RS$60
(MHC-bead assay). High affinity peptide controls: CMV-NLVPMVATV
(green), FLU-GILGFVFTL (pink), EBV-GLCTLVAML (orange) and HA1-
VLHDDLLEA (red). Low affinity peptide control: MART1-AAGIGILTV
(blue) and negative control A3-gp100-LIYRRRLMK (grey).
doi:10.1371/journal.pone.0022523.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22523Figure 2. Detection of potential MiHA specific T-cell populations by pMHC tetramer staining. These FACS analyses show the detection of
MiHA specific T-cell populations through dual-encoding after pMHC tetramer pull down and in vitro expansion. Shown are total CD8
+ T-cells. All dot
plots are shown with bi-exponential axes and display fluorescence intensity for the indicated fluorochromes at the top and right of the plot matrix.
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clone that is specific for the HMHA-1H epitope. This T-cell clone
has been demonstrated to be present in a GVL response and was
obtained during the subsequent memory phase. The 8 cell lines
tested showed a wide range of peptide sensitivity. Specifically, the
cell lines specific for P218 MAP4K1IMA and P46 HMHA1VLH
were capable of target recognition at low picomolar peptide
concentrations, similar to the peptide concentration required for
the HMHA-1-specific control T-cell clone. Cell lines specific for
P91 FLT3KVL, P309 HSPA6SMC and P188 FLT3ALA required low
Non-pMHC tetramer specific CD8
+ T-cells are indicated black. Dot plots of pMHC tetramer positive T-cell populations are shown by staining one
expanded cell culture with 16 separate panels of up to 25 different dual-color pMHC tetramers. (a) Representative example of pMHC multimer screen
panel 5, patient BDY3356. Detection of three dual-labeled potential MiHA specific T-cell populations: P89 ITGAMRLQ (red), P104 ZFP36L2RLL (blue) and
P109 FMNL1SLW (green). Frequencies indicate MiHA specific T-cells of total CD8
+ cells. A selection of 21 potential MiHA specific T-cell populations was
made with the highest clinical potential. Selected T-cell populations were derived from allo-SCT patient: OBB1465 (b), JMO2750 (c), BDY3356 (d) and
APM4461 (e). Dot plots shown are representative for all detected dual-positive CD8
+ T-cell populations (red).
doi:10.1371/journal.pone.0022523.g002
Figure 3. Peptide stimulation leads to IFN c production and TCR downregulation for 10 out of 17 pMHC tetramer positive cell lines.
Isolated pMHC tetramer positive cell lines were stimulated with peptide-loaded HLA-A2
+ T2 target cells for 18 hours. Data is shown for 17 cell lines
that were successfully generated by flowcytometry based cell sorting. Tested cell lines were derived from four different allo-SCT patients as indicated
at the top of the graph. As a control an alloreactive CTL clone specific for a HLA-A2 epitope was used (Allo-A2). (a) Antigen specificity and
functionality was analyzed by cytokine secretion in a standard IFN c ELISA. Cell lines were stimulated with non-peptide loaded T2 cells (dark grey),
[1 ug/ml] peptide-loaded T2 cells (black) and aCD3/CD28 stimulation beads (light grey). Data are presented as cytokine concentration. (b) Antigen
specificity and functionality was analyzed by TCR internalization upon peptide stimulation. Cell lines shown were stimulated with [1 ug/ml] peptide-
loaded T2 cells (black) and aCD3/CD28 stimulation beads (light grey). TCR downregulation was normalized to stimulation with non-peptide loaded T2
cell controls. Experiments were performed in duplicate, data are mean 6 SD.
doi:10.1371/journal.pone.0022523.g003
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DOCK2SIQ, P203 ATP2A3KMN and P104 ZFP36L2RLL only
showed target recognition at high nanomolar peptide concentra-
tions (IC50: 650 pM, 65 nM and 6500 nM respectively for the
three groups of cell lines). Comparison of the peptide concentra-
tion required for T-cell activation and the MHC binding affinity of
the different peptides indicated that a requirement for high peptide
concentrations to obtain T-cell activation was not simply due to a
lower pMHC affinity. As an example, the peptides recognized by
cell-lines P91 FLT3KVL and P203 ATP2A3KMN displayed a
comparably high MHC affinity (as measured in Fig. 1) as those of
the two highly sensitive cell lines P218 MAP4K1IMA and P46
HMHA1VLH. Thus, the low peptide sensitivity of many of the
isolated T-cell lines formed a direct reflection of a low affinity
TCR-pMHC interaction.
Isolated T-cell populations are not involved in the clinical
response
To determine whether the observed T-cell reactivities could be
involved in the clinical response observed after DLI in these
patients, we screened the high- and intermediate-avidity T-cell
lines for differential recognition of patient- and donor-derived
EBV-LCLs and T-cell-blasts. Results are shown for 5 represen-
tative T-cell lines isolated from patient BDY3356 and JMO2750
(figure 5a,b). Peptide loaded target cells of both donor and
recipient origin were recognized by all cell lines. In contrast, all cell
lines were unable to recognize recipient target cells, indicating that
these cells were not likely to be involved in the GVL response
observed in these patients. As a control, all hematopoietic target
cells were recognized by an HLA-A2 alloreactive CTL control
clone, indicating that HLA-A2 expression was sufficient to allow
target-cell recognition. Notably, recognition of recipient cells was
also not observed for the HMHA-1 specific cell-line.
To test whether the lack of reactivity that was observed could
be explained by absence of the immunogenic MiHA allele
variants, we next screened the SNP haplotypes for selected
donor-recipient pairs (Table 1). For 15 out of the 17 functionally
tested cell lines, no SNP haplotype disparities were revealed for the
potential MiHA concerned. In addition, only 7 out of 15 tested cell
lines recognized ‘‘non-self’’ antigen variants (i.e. the variant not
encoded by the donor genome), whereas 8 cell lines recognized
‘‘self’’ antigen variants. Interestingly, both high-avidity T-cell
populations that were isolated (specific for P218 MAP4K1IMA and
P46 HMHA1VLH) recognized ‘‘non-self’’ antigen variants, where-
as all cell lines that recognized ‘‘self’’ antigen variants were of
intermediate or low-avidity. These results suggest a possible role
for clonal deletion of high-avidity T-cells specific for these ‘‘self’’
epitopes when they are appropriately processed. Based on these
results, we hypothesized that the low or intermediate avidity of
most MiHA specific cell lines that we generated could explain the
inability of these cell lines to recognize endogenously processed
antigen. The only two cell lines that were derived from a trans-
plantation setting in which there was a relevant SNP mismatch
between the donor and recipient were specific for P23 CD79bLLL
and P109 FMNL1SLW. Although these cell lines could theoreti-
cally recognize the immunogenic MiHA allele variant of the
patient, both cell lines demonstrated no recognition of endoge-
nously processed antigen in the prior functional analyses.
Assessing the MiHA recognition potential of isolated
T-cell populations
The above data indicate that unbiased MHC tetramer-based
enrichment often results in the isolation of T-cell populations that
do not play a role in GVL, as based on the lack of the relevant
mismatch. However, this does not exclude that such cell popu-
lations could recognize target cells that do express the relevant
MiHA allele. To investigate the potential capacity of these MiHA
specific T-cell populations to recognize MiHA allele -positive
target cells, the cell lines were tested against a panel of SNP-
genotyped HLA-A2
+ EBV-LCLs. Interestingly, the HMHA-1
specific T-cell population, isolated from a transplantation setting in
which both donor and recipient were homozygous negative for the
immunogenic allele variant of the MiHA, recognized target cells in
accordance with their SNP haplotype. Specifically, this tested cell
line strongly recognized non-peptide loaded homozygote positive
and heterozygote EBV-LCLs, whereas homozygote negative EBV-
LCLs were not recognized. In contrast, the second high avidity
P218 MAP4K1IMA specific cell-line, as well as the intermediate
avidity cell lines were unable to recognize any target in the SNP-
typed EBV-LCL panel.
Lack of target cell recognition by high-avidity T-cells is
caused by inappropriate processing and surface
presentation of predicted epitope
The P218 MAP4K1IMA specific T-cell population demonstrated
efficient recognition of target cells loaded with picomolar con-
centrations of peptide, whereas no reactivity was observed in
accordance with the SNP haplotype of tested targets. To
determine whether the inability of this high avidity T-cell line to
recognize endogenously processed antigen was due to the inability
of the target cells to process and present the MAP4K1IMA epitope,
a retroviral minigene vector was constructed that encoded the
minimal MAP4K1IMA peptide sequence directly attached to an
ER-signal sequence [32]. In this design, delivery of the potential
T-cell epitope to the ER occurs co-translationally, and hence
independent of proteasomal processing and TAP transport. As a
positive control, a similar minigene was created for the HMHA-
1H epitope. HLA-A2
+ JY cells that are homozygous negative for
both the P218 MAP4K1IMA and the HMHA-1H allele were
transduced with the two minigene constructs, and demonstrated to
be recognized by the HMHA-1 T-cell line as well as by the
MAP4K1IMA specific T-cell line (Figure 6). These results indicate
Figure 4. Analysis of peptide affinity of pMHC tetramer
positive cell lines MHC tetramer positive T-cell lines demon-
strated a wide range of peptide sensitivity. HLA A2
+ T2 cells were
pulsed with specific MiHA peptide. Peptide concentrations were titrated
in 10-fold dilution steps starting from 10ug/ml. T-cell reactivity was
analyzed by cytokine secretion in a standard IFN c ELISA. Data are
presented as cytokine concentration. Shown are eight representative
generated T-cell lines and a high affinity control clone specific for
HMHA-1H (open square). Cell lines APM4461 derived P37 DOCK2SIQ and
JMO2750 P185 HSPA6FMT were not tested due to technical limitations.
doi:10.1371/journal.pone.0022523.g004
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epitope is forced, recognition by P218 MAP4K1IMA specific T-
cells is strong.
Discussion
This study demonstrates the feasibility and limitations of using a
reverse immunology approach for the identification of potential
MiHA. We combined large scale prediction of HLA-restricted
MiHA with functional assessments of these polymorphic epitopes
by identifying MiHA specific T-cell populations in a high-
throughput unbiased fashion. In this study we used a reverse
immunology approach, based on UV-induced peptide exchange
technology, in which the predicted MiHA epitopes were the
starting point for identification of new MiHA specific T-cell
responses. By investigating MiHA source proteins with a
hematopoietic tissue restricted expression pattern, we aimed to
identify potential CTL epitopes that would selectively target
recipient hematopoiesis.
The combined use of three prediction programs resulted in the
generation of a synthetic peptide library of 973 experimental
peptides encoded by hematopoietic stem cells. The MHC binding
capacity of these peptides was verified by UV-induced MHC-
peptide exchange. Based on the binding capacity of well studied
natural ligands, we estimate that one third of the predicted peptide
set could be defined as high affinity, one third as intermediate
affinity and one third as low affinity HLA-A2.
To assess the ability of these epitopes to serve as TCR ligands
we monitored T-cell responses in a high throughput unbiased
fashion using multiplexed fluorescently labeled sets of pMHC
Figure 5. No recognition of hematopoietic donor and recipient target cells by MiHA specific T-cells. Isolated IFN c producing cell lines
were stimulated with HLA-A2
+ donor and patient derived hematopoietic target cells for 18 hours. T-cell reactivity was measured in a standard IFN c
ELISA. Data are presented as cytokine concentration. Cell lines shown are representative for all cell lines. As a control for T-cell reactivity an
alloreactive HLA-A2 specific CTL clone was used (black). (a) BDY3356 derived cell lines P37 DOCK2SIQ (white), P203 ATP2A3KMN (dark grey) and P218
MAP4K1IMA (light grey) stimulation with donor and recipient T-cell blasts and EBV-LCLs loaded with (+) or without (2) specific peptide [1 ug/ml]. (b)
JMO2750 derived cell lines P104 ZFP36L2RLL (dark grey) and P188 FLT3ALA (light grey) stimulation with donor and recipient T-cell and EBV blasts
loaded with (+) or without (2) specific peptide [1 ug/ml].
doi:10.1371/journal.pone.0022523.g005
High-Throughput MiHA Identification
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22523complexes. We were able to detect epitope specific T-cell
recognition for 71 of the 333 screened pMHC complexes of
which 24 epitopes were recognized in multiple and 47 epitopes
were recognized in single individuals. Taken into account that
these T-cells were isolated from small cell size PBMC samples of
allo-SCT patients with only partially reconstituted TCR reper-
toires, this data highlights both the immense capacity of the TCR
repertoire to recognize random HLA-ligands and the high-
sensitivity of our enrichment protocol. Unfortunately, most
isolated pMHC tetramer positive T-cells appeared to be of low
or intermediate avidity. Two cell lines recognized their respective
peptide with high avidity. In the case of MAP4K1IMA,n o
reactivity against endogenously processed antigen was observed,
but cells expressing a minigene encoding this epitope were
efficiently recognized, suggesting that inappropriate processing
explains the lack of recognition of epitope derived from the
parental protein. The second high avidity T-cell population
recognized the HMHA-1H epitope, and target cell recognition by
the T-cell line fully matched HMHA-1 status.
As the identification of the HMHA-1 and MAP4K1IMA specific
T-cell responses in our experiments occurred in a fully unbiased
screen, this forms evidence that the type of genome-wide screen
developed here can be successful. Nevertheless, the fact that only
the HMHA-1 specific T-cell population showed recognition of
endogenously produced antigen shows that this discovery process
is still highly suboptimal, and we see 3 major areas for
improvement for this.
First, the capacity of a specific T-cell to bind to a pMHC
tetramer does not necessarily reflect its capacity to elicit potent T-
cell reactivity when stimulated with a relevant pMHC complex. In
this study only 2 out of the 16 T-cell populations that produced
IFN c upon nonspecific stimulation also demonstrated IFN c
production (and TCR internalization) at picomolar range peptide
concentrations. Importantly, these high-avidity T-cell populations
do not necessarily demonstrate a more intense pMHC tetramer
staining intensity as compared to low and intermediate avidity T-
cell populations, making it difficult to weed out less interesting T-
cell populations on the basis of MHC tetramer staining intensity.
Thus, alternative strategies are required to obtain a rough estimate
of T-cell sensitivity early in the screening process.
Second, in this screen, T-cell populations were isolated using the
full set of pMHC tetramer complexes for each sample, irrespective
of SNP status of donor and recipient. The frequent encounter of
low avidity pMHC tetramer positive T-cells from donors for which
this epitope forms a ‘‘self’’ antigen could therefore reflect clonal
deletion of high avidity T-cells, due to presentation of the
predicted epitopes in the donor thymus. In future screens it seems
Table 1. MiHA haplotype disparities in selected donor and recipient pairs.
Clone Gene Epitope
a
Epitope
allele variant
Donor
allele
Patient
allele Disparity
b
Clonal
nature
P4 PLCB2 R I L V G R L R A A A AG AA no Self
P23 CD79b L L L S A E V Q Q H L A GG AG yes non-self
P37 (BDY) DOCK2 S I Q N Y H P F A A AA AA no Self
P37 (APM DOCK2 S I Q N Y H P F A A AA AA no self
P46 HMHA1 V L H D D L L E A A GG GG no non-self
P89 ITGAM R L Q V P V E A V G GG GG no self
P91 FLT3 K V L H E L F G M D I A AA AA no self
P104 ZFP36L2 R L L P L W A A L P L G GG GG no self
P109 FMNL1 S L W Q L G A A V M L G CC CG yes non-self
P153 DOCK2 K L L Q I Q L R A G GG GG no self
P203 ATP2A3 K M N V F D T N L A GG GG no non-self
P218 MAP4K1 I M A I E L A E L A GG GG no non-self
P235 (APM) PRKCB1 R I G Q R Q E T V G AA AA no non-self
P235 (JMO) PRKCB1 R I G Q R Q E T V G AA AA no non-self
P309 HSPA6 S M C R F S P L T L A AG AG no self
aPolymorphic residue in italic.
bDisparities are indicated in respect to the donor haplotype.
doi:10.1371/journal.pone.0022523.t001
Figure 6. Recognition of EBV target cells by high-avidity MiHA
T-cells after minigene transduction. High-avidity cell lines P46
HMHA1VLH (white) and P218 MAP4K1IMA (grey) were stimulated with
HLA-A2
+ EBV-LCL JY transduced with minigene constructs (MG)
encoding minimal peptide sequence directly attached to an ER-signal
sequence. T-cell reactivity was measured after 18 hours in a standard
IFN c ELISA. Data are presented as cytokine concentration. The MOCK
transduced cells only encoded an ER-signal sequence. As a control for T-
cell reactivity an alloreactive HLA-A2 specific CTL clone was used
(black).
doi:10.1371/journal.pone.0022523.g006
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throughput analysis to those epitopes that can be considered neo-
antigens in a given transplant combination, something that can
readily be done by evaluation of donor (and recipient) SNP status.
Third, of the two high avidity T-cell populations isolated, only
one could recognize epitopes derived from the endogenous
antigen. In this project ligand prediction focused solely on the
HLA affinity of predicted peptides and disregarded other aspects
of the HLA processing and presentation pathway. As a con-
sequence, many of the predicted epitopes used here may not
be part of the natural peptidome and thereby lack biological
relevance. In future work, this issue may to some extent be
addressed by the use of antigen processing algorithms that predict
proteosomal cleavage and TAP-dependent peptide transport [33,
34]. As a second, and in our view even more attractive option, the
peptide set used for high-throughput screening could be derived
from a database of HLA eluted peptides, thereby guaranteeing
presentation of the epitopes concerned.
In conclusion, our isolation and detailed analysis of potential
MiHA candidates in a high-throughput fashion has revealed the
technical feasibility of this reverse immunology approach. We have
demonstrated that TCR repertoires against very large sets of
antigens can rapidly be screened. However, the productive use of
such high-throughput screening technology will require further
improvements. In particular, stringent epitope selection criteria
including the availability of high quality databases of MHC ligands
and SNP genotypes are likely to be of value to increase the
percentage of isolated T-cell populations that is not only pMHC
tetramer reactive but also biologically relevant.
Materials and Methods
PBMC samples and T-cell staining
After study approval of the Leiden University Medical Center
institutional review board, PBMC samples were obtained from
allo-SCT patients during the memory phase of a graft versus
leukemia response after DLI as determined by mixed hematopoi-
etic chimerism and/or quantitative BCR-ABL analysis after
approval of the Leiden University Medical Center institutional
review board and informed consent according to the Declaration
of Helsinki. Informed consent form all participants involved in this
study were written for samples obtained since 2003 and verbal for
older samples when guidelines provided no written consent.
PBMC were isolated by Ficoll gradient centrifugation, and frozen
in liquid nitrogen. For T-cell staining of approximately 1610
6
PBMC a final concentration of 2 mg/mL per pMHC tetramer was
added and incubated for 15 min at 37uC. Next, antibody-mix
consisting of CD8-Alexa700 (Caltag) and CD4-, CD14-, CD16-,
CD19- and CD40-FITC (BD) was added and cells were incubated
for 30 min at 4uC. Prior to flow cytometry, cells were washed
twice and Propidium lodide (PI) was added to allow dead cell
exclusion. Dual-encoding pMHC tetramer analysis was performed
as previously described [20].
Gene expression of hematopoietic cell fractions by
microarray analysis
Hematopoietic precursor CD34
+ cells were isolated by MACS
(Miltenyi) from bone marrow; G-CSF mobilized peripheral blood
and cord blood PBMC according to manufacturer’s protocol.
Total RNA was isolated using Trizol (Invitrogen) and transcribed
into cDNA by reverse transcriptase (Invitrogen) using oligo-dT
primers (Roche Diagnostics). Microarray analysis of gene
expression profiles in CD34
+/CD38
2 and CD34
+/CD38
+ frac-
tions was performed by Affymetrix U133 array according to the
manufacturer’s instructions. Additional gene expression informa-
tion was retrieved from the NCBI Gene Expression Omnibus
database [23].
Prediction of HLA-A2
+ MiHA ligands
The following prediction algorithms were applied to the peptide
candidates: Syfpeithi [25], Bimas [26] and netMHC [27]. Peptides
with a score of $19 (Syfpeithi), $1 (Bimas) and #875 (netMHC)
were considered to have potential HLA-A2
+ binding capacities.
SNP data was retrieved from NCBI’s dbSNP polymorphism
database [24]. Amino acid sequences were obtained from NCBI
Entrez engine.
Generation of peptide-MHC complexes
All peptides were synthesized in-house using standard Fmoc
chemisty or purchased from Pepscan (Pepscan Presto). The UV-
sensitive building block J was synthesized as described [18].
Recombinant HLA-A2 heavy chain and human b2m light chain
were in-house produced in Escherichia coli. MHC class I refolding
was performed as previously described with minor modifications
[20]. MHC class I complexes were purified by gel-filtration HPLC
in PBS. Peptide-MHC complexes were generated by MHC-
peptide exchange. Prefolded UV-liable pMHC complexes (100 mg/
ml) were subjected to 366nm UV light (Camag) for 1 h in presence
of the specific peptide (200 mM) [19,28]. After exchange, samples
were spun at 16,000 g for 5 min and supernatants were used for
pMHC tetramer formation. The peptide HLA-A2
+ binding affinity
was assessed using two different HLA-binding assays in parallel;
MHC-ELISA and MHC bead as previously described [18,29]. For
generation of pMHC tetramers, 8 different fluorochrome-strepta-
vidin (SA) conjugates were used as previously described [20].
Phycoerythrin (PE), allophycocyanin (APC) and the quantum dots
(QD);QD565,QD585,QD605,QD655,QD705andQD800were
used (Invitrogen). Complexes were stored at 4uC and prior to use
pMHC tetramers were spun at 17.000 g for 2 min.
Isolation of MiHA specific T-cells by pMHC tetramer pull
down
Prior to isolation of peptide-specific T-cells, pMHC tetramers
were made coupled to SA-PE. PBMC were stained with pMHC
tetramers for 1 hour at 4uC. Subsequently, cells were washed and
incubated with anti-PE Ab coated magnetic beads (Miltenyi). Cells
were than isolated by MACS (Miltenyi), using an LS column,
following the manufacturers protocol. Eluted cells were washed
and cultured in Iscove Modified Dulbecco Medium (IMDM;
Lonza BioWhittaker) supplemented with 5% human serum, 5%
fetal calf serum (FCS; Cambrex), 100 IU/mL IL-2 (Chiron),
10ng/mL IL-15 (Peprotech). Eluted cells were cultured per 5000
cells with 2610
4 irradiated autologous feeder cells and 5000 anti-
CD3/CD28 Dynabeads (Invitrogen) in 96-well plates. Cultures
were split at least twice a week. After 2–3 weeks, cell cultures were
analyzed for peptide-specific T-cell populations by pMHC
tetramer flow cytometry. Subsequently pMHC tetramer reactive
T-cell populations were sorted on a FACSAria (Becton Dickinson)
into 96 well plates containing 1610
5 irradiated feeder cells
supplemented with 0.5 mg/mL phytohaemagglutinin (PHA; Bio-
chrom AG) as previously described [35].
Flow cytometry
Data acquisition was performed on an LSR-II flow cytometer
(Becton Dickinson) with FacsDiva software using the following 11-
color instrument settings: 488nm laser: PI: 685LP, 695/40; PE:
550LP, 575/26; FITC: 505LP, 530/30; SSC: 488/10. 633nm
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QD800: 770LP, 800/30; QD705: 680LP, 710/50; QD655:
635LP, 660/40; QD605: 595LP, 650/12. 355nm laser: QD585:
575LP, 585/15; QD565: 545LP: 560/20. Approximately 200,000
lymphocytes were recorded for each analysis. To identify antigen-
specific T-cells we followed the gating strategy as described in
Figure S2.
IFN c release assay
MiHA specific T-cell lines (1610
4) were stimulated with HLA-
A2
+ T2 cells, EBV-LCLs or T-cell blasts (2,5610
4) in 96 well
plates for 18 h at 37uC and 5% CO2. Peptide pulsing was
performed by incubating stimulator cells for 1 h with synthetic
peptides (1 mg/ml) in IMDM containing 2% FCS and cells were
washed twice before use. Cytokine release was measured by IFN c
ELISA (Sanquin) according to the manufacturer’s instructions.
Supporting Information
Figure S1 Gene expression profiles and MiHA predic-
tion of hematopoiesis-restricted genes obtained with
microarray analysis. Gene expression profiles of CD34
+/
CD38
2 and CD34
+/CD38
+ hematopoietic precursor cell popu-
lations. On the x-axis 100 different tissues or cell material are
shown, clustered by organ system. On the y-axis the mRNA
expression of the gene is shown. SC: stem cells, BM: bone marrow,
PB: peripheral blood, Imm: immunological tissues, Apc: antigen
presenting cells, Mal: hematological malignancies, CNS: central
nervous system. Repr: reproductive organs, Gla: endocrine glands:
Conn: connective tissues, Li: liver, Lu: lung, Dig: digestive tracts,
Hea: heart, SK: skin, EC: endothelial cells. (a,b) HMHA-1 and
PTPRC (CD45) have a clear hematopoiesis-restricted gene
expression pattern. (c) Prostate kallikrein 2 (KLK2) demonstrate
a tissue-specific gene expression pattern. (d) glyceraldehyde-3-
phosphate dehydrogenase (GAPD) is ubiquitously expressed. (e,f)
Integrin beta 2 (ITGB2) and FMS-like tyrosine kinase 3 (FLT3)
were identified as genes (2 out of 78) with a hematopoiesis-
restriced gene expression pattern by data-mining the combined
microarray database. MiHA prediction based on peptide sequenc-
es representing the nucleotide sequences of both allelic variants of
a SNP using three HLA-peptide binding algorithms. Polymorphic
residue encoding triplet is highlighted (grey) and start-codon is
underlined. ARF: alternative reading frame, NRF: normal reading
frame S: Syfpeithi [25], B: Bimas [26], N: netMHC [27]. (*): Only
N was used to predict 11-mers HLA-binding. Selection threshold
S: binding score (BS) $19, B: BS$1, N: BS#500. (g) Prediction of
MHMA-1 epitopes for RH139 polymorphism. Described immu-
nogenic MiHA epitope; MHMA-1H and allelic variant are
highlighted (red). (h) Prediction of ITGB2 epitopes for KE630
polymorphism.
(PDF)
Figure S2 Flowcytometric analysis of pMHC tetramer
specific cell lines. Flowcytometric analysis of HMHA-1
specific T-cells in an allo-SCT patient sample obtained
15 months after DLI, during the memory phase of the
GVL response.( a) Life gating strategy to reduce background
pMHC tetramer staining. FSC and SSC width and height
channels were used to reduce background staining. Propidium
iodide (PI) was used as a death cell marker. In all plots total
lymphocytes are grey, total CD8
+ T-cells are black and pMHC
tetramer positive T-cells are highlighted red. Dot plots are shown
with bi-exponential axes and display fluorescence intensity for the
indicated fluorochromes. (b) Flowcytometric analysis of HMHA-1
specific T-cells after pull down and in vitro expansion. pMHC
tetramer positive T-cell frequencies are expressed as total CD8
+ T-
cells. (c,d) Flowcytometric purity analysis of pMHC tetramer
specific cell lines. Dot plots show total lymphocytes (black). Dot
plots are shown with bi-exponential axes and display fluorescence
intensity for the specific pMHC tetramer complexes on the x-axis
and CD8 expression on the Y-axis. Shown frequencies indicate
pMHC tetramer positive T-cells out of total lymphocytes. (c)
BDY3356 derived CD8
+ cell line: P37 DOCK2SIQ.( d) APM4461
derived CD8
+ cell line: P46 HMHA1VLH. Dot plots shown are
representative for all generated cell lines.
(PDF)
Table S1 Identified genes with a hematopoiesis-re-
sricted expression pattern.
(PDF)
Table S2 Total MiHA epitopes predicted by HLA-
peptide binding algorithm.
(PDF)
Table S3 Dual-encoding pMHC tetramer scheme.
(PDF)
Table S4 Total pMHC tetramer-reactive T-cell popula-
tions revealed after pull down and two weeks of
expansion.
(PDF)
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